222 related articles for article (PubMed ID: 22993907)
1. [Portal vein thrombosis as the main symptom of unclassified JAK2-positive myeloproliferative neoplasm--case report].
Karakulska-Prystupiuk E; Gierej B; Paszkowska-Kowalewska M; Wilkowojska U; Jedrzejczak WW
Pol Merkur Lekarski; 2012 Jul; 33(193):29-31. PubMed ID: 22993907
[TBL] [Abstract][Full Text] [Related]
2. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
3. Concomitant diagnosis of myeloproliferative neoplasm and non-Hodgkin's lymphoma in a patient with portal vein thrombosis.
Papageorgiou MV; Alexopoulou A; Kontopidou F; Filiotou A; Koskinas J; Pectasides D
Anticancer Res; 2011 Apr; 31(4):1467-9. PubMed ID: 21508404
[TBL] [Abstract][Full Text] [Related]
4. [Recurrent deep vein thrombosis and myeloproliferative syndrom: emergence of JAK2 mutation five years after the initial event].
Salort A; Seinturier C; Molina L; Lévèque P; Imbert B; Pernod G
J Mal Vasc; 2014 May; 39(3):207-11. PubMed ID: 24721000
[TBL] [Abstract][Full Text] [Related]
5. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
6. Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
de Suray N; Pranger D; Brenard R
Acta Gastroenterol Belg; 2008; 71(1):39-41. PubMed ID: 18396750
[TBL] [Abstract][Full Text] [Related]
7. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
8. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis.
Primignani M; Barosi G; Bergamaschi G; Gianelli U; Fabris F; Reati R; Dell'Era A; Bucciarelli P; Mannucci PM
Hepatology; 2006 Dec; 44(6):1528-34. PubMed ID: 17133457
[TBL] [Abstract][Full Text] [Related]
9. A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation.
Galati G; Gentilucci UV; Sansoni I; Spataro S; Di Matteo FM; Zardi EM; Grasso RF; Avvisati G; Afeltra A; Picardi A
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):233-6. PubMed ID: 19212214
[TBL] [Abstract][Full Text] [Related]
10. [Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
Araki N; Takimoto R; Chiba H; Araki H; Sato T; Iyama S; Hirakawa M; Ono K; Kawano Y; Takada K; Miyanishi K; Kobune M; Matsunaga T; Kato J; Nakamura T; Niitsu Y
Rinsho Ketsueki; 2007 Jul; 48(7):554-8. PubMed ID: 17695304
[TBL] [Abstract][Full Text] [Related]
11. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
13. [Deep vein thrombosis revealing myeloproliferative syndrome in two adolescents].
Bertrand A; Heissat S; Caron N; Viremouneix L; Pracros JP; Javouhey E; Lachaux A; Mialou V
Arch Pediatr; 2014 May; 21(5):497-500. PubMed ID: 24709317
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
[No Abstract] [Full Text] [Related]
15. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
16. JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
Villani L; Bergamaschi G; Primignani M; Rosti V; Carolei A; Poletto V; Catarsi P; Spolverini A; Vannucchi AM; Barosi G
Leuk Res; 2012 Jan; 36(1):e7-9. PubMed ID: 21890200
[No Abstract] [Full Text] [Related]
17. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Hussein K; Bock O; Kreipe H
Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
[TBL] [Abstract][Full Text] [Related]
18. Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis.
Gianelli U; Iurlo A; Cattaneo D; Bossi A; Cortinovis I; Augello C; Moro A; Savi F; Castelli R; Brambilla C; Bianchi P; Primignani M; Cortelezzi A; Bosari S
Leuk Res; 2015 May; 39(5):525-9. PubMed ID: 25840747
[TBL] [Abstract][Full Text] [Related]
19. Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Gianotti R; Charles H; Hymes K; Chandarana H; Sigal S
World J Gastroenterol; 2014 Oct; 20(39):14495-9. PubMed ID: 25339837
[TBL] [Abstract][Full Text] [Related]
20. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
[No Abstract] [Full Text] [Related]
[Next] [New Search]
